| Bioactivity | Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3]. |
| Name | Mezagitamab |
| CAS | 2227490-52-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9. [2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. [3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. |